The following biochemical biomarkers for AD diagnosis have been established: decreased CSF Aβ42 levels, decreased Aβ42/40 ratio, increased p-Tau/Aβ42 ratio, and increased total Tau (t-Tau)/Aβ42 ratio7,8. Here, MAPT is linked to Alzheimer disease.